The increased use of generics in Germany has brought about record savings of more than 25% in 2011 compared with 2010. The increased savings have been attributed to the success of measures put in place by the German Government to encourage generics substitution and competition in the public health insurance funds off-patent market.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- FDA approves filgrastim biosimilar Filkri
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
- EMA recommends approval for teriparatide biosimilar Zandoriah
- FDA approves third interchangeable ranibizumab biosimilar Nufymco
Research
- OECD study finds no direct link between advertising rules and biosimilar uptake
- Reaching ESG goals in pharmaceutical development
- What is the future for the US biosimilar interchangeability designation
- Biosimilar clinical efficacy studies: are they still necessary?
- MORE EDITORIAL SECTIONS
- Search




Post your comment